Preclinical studies have shown that breast cancer cell lines with alterations in the PI3K/Akt/mTOR pathway, such as activating PIK3CA mutations or HER2 amplification, are sensitive to PI3K/Akt/mTOR pathway inhibition [24],[26],[60]. This evidence concerns the gene PIK3CA and breast carcinoma.